MiMedx(MDXG) ZACKS·2025-02-26 23:55Financial Performance - MiMedx reported quarterly earnings of 0.04 per share a year ago [1] - The company posted revenues of 86.83 million in the same quarter last year [2] - Over the last four quarters, MiMedx has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - MiMedx shares have declined approximately 17.3% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is 86 million, and for the current fiscal year, it is 375 million [7] - The trend of estimate revisions for MiMedx is mixed, which could change following the recent earnings report [6] Industry Context - MiMedx operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 24% of over 250 Zacks industries [8] - Research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]